Share Price and Volume Have Rocketed After a Lull-Flat @ $.15 Then a Dip to a Low of $.09 (Feb 5th)Currently Approximately ($.35/$.38) Up 31% Today -Up 290% Since Feb 5th
Regen BioPharma Inc. Announces Preferred Stock Dividend
SAN DIEGO, CA, Feb 24, 2015 (Marketwired via COMTEX) -- Regen BioPharma Inc. (OTCBB: RGBP) announced today that its Board of Directors has declared a stock dividend to common shareholders of record as of March 10, 2015 to be paid to shareholders on or about March 20, 2015.
**Common shareholders will be entitled to receive one share of Series A Preferred Stock for every 10 shares of Regen Biopharma, Inc. common Stock owned as of the Record Date.
Regen BioPharma, Inc. Comments on dCellVax Cancer IDO-Targeting Technology in Relation to Bristol Myers Squibb-Flexus Biosciences, Inc. AnnouncementCompany Sees Recent Pharma Deal as Positive Validation of Its IDO-Targeting TechnologySAN DIEGO, CA, Feb 24, 2015 (Marketwired via COMTEX) -- Regen BioPharma, Inc. (OTCQB:RGBP) commented on the recently announced definitive agreement between Bristol Myers Squibb and Flexus Biopharma, Inc. in which all outstanding shares of Flexus Biosciences Inc. will be purchased for $800 million upfront and development milestones that, upon achievement, could total up to $450 million(1).
**Thomas Ichim PhD-Chief Scientific Officer-Board Member
Orchestrated the Merger/Sale Acquisition of MediStem by Intrexon
**(OTCQB:RGBP) is Primed for AcquisitionRGBP). The Company is focused on identifying undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy for treating cancer, telomeres and small molecule therapies, along with developing stem cell treatments for aplastic anemia.
ABOUT REGEN BIOPHARMA INC.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB:
The Company currently has an IND (Investigational New Drug Application #16200) filed with the FDA on, the Company's gene silencing product known as dCellVax. dCellVax when approved by the FDA will be implemented and used to combat and reverse Breast Cancer in live Human Clinical Trials.www.otcmarkets.com
The Company also has an IND filed with the FDA on its HemaXellerate product for treating aplastic anemia (#15376). This product uses a patient's own stem cells to stimulate the production of blood. Currently FDA is reviewing protocols submitted by the Company for conducting an additional GLP safety study before clinical trials can begin.
The Third patented technology(New Drug) NR2F6, a new drug target, is essential in development and maintenance of leukemia and myelodysplastic syndrome.
** For All News/PR and Due Diligence, please visit
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.